Increased inflammasome related gene expression profile in PBMC may facilitate T helper 17 cell induction in multiple sclerosis

Molecular Immunology

Volumn 63, Issue 2, 2015, Pages 521-529

  Peelen, E ^a,b   Damoiseaux, J ^a   Muris, A H ^a,b   Knippenberg, S ^a,b   Smolders, J ^c   Hupperts, R ^a,b   Thewissen, M ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Sittard Geleen Heerlen   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Inflammasome; Multiple sclerosis; NLRP3; T helper cells; Th17

Indexed keywords

CALCITRIOL; CRYOPYRIN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INFLAMMASOME; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; MESSENGER RNA; ADENOSINE TRIPHOSPHATE; LIPOPOLYSACCHARIDE; VITAMIN D;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; MALE; MULTIPLE SCLEROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; SUPERNATANT; TH17 CELL; BLOOD; CASE CONTROL STUDY; CELL FRACTIONATION; DOWN REGULATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; PATHOLOGY; SECRETION (PROCESS); YOUNG ADULT;

ADENOSINE TRIPHOSPHATE; ADULT; CASE-CONTROL STUDIES; CELL DIFFERENTIATION; DOWN-REGULATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; INFLAMMASOMES; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-10; INTERLEUKIN-17; INTERLEUKIN-1BETA; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; SUBCELLULAR FRACTIONS; TH17 CELLS; VITAMIN D; YOUNG ADULT;

EID: 84912033385     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2014.10.008     Document Type: Article

References (39)

1. Argaw A.T., et al. IL-1beta regulates blood-brain barrier permeability via reactivation of the hypoxia-angiogenesis program. J. Immunol. 2006, 177(8):5574-5584.
2. Basu A., et al. Transforming growth factor beta1 prevents IL-1beta-induced microglial activation, whereas TNFalpha- and IL-6-stimulated activation are not antagonized. Glia 2002, 40(1):109-120.
3. Basu R., Hatton R.D., Weaver C.T. The Th17 family: flexibility follows function. Immunol. Rev. 2013, 252(1):89-103.
4. Burger D., et al. Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1beta in human monocytes and multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 2009, 106(11):4355-4359.
5. Cannella B., Raine C.S. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann. Neurol. 1995, 37(4):424-435.
6. Coclet-Ninin J., Dayer J.M., Burger D. Interferon-beta not only inhibits interleukin-1beta and tumor necrosis factor-alpha but stimulates interleukin-1 receptor antagonist production in human peripheral blood mononuclear cells. Eur. Cytokine Netw. 1997, 8(4):345-349.
7. Codarri L., et al. RORgammat drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat. Immunol. 2011, 12(6):560-567.
8. Crusius J.B., et al. Interleukin-1 receptor antagonist gene polymorphism and multiple sclerosis. Lancet 1995, 346(8980):p979.
9. de Jong B.A., et al. Production of IL-1beta and IL-1Ra as risk factors for susceptibility and progression of relapse-onset multiple sclerosis. J. Neuroimmunol. 2002, 126(1-2):172-179.
10. El-Behi M., et al. The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF. Nat. Immunol. 2011, 12(6):568-575.
11. Evans R.J., et al. Mapping receptor binding sites in interleukin (IL)-1 receptor antagonist and IL-1 beta by site-directed mutagenesis. Identification of a single site in IL-1ra and two sites in IL-1 beta. J. Biol. Chem. 1995, 270(19):11477-11483.
12. Fabriek B.O., et al. In vivo detection of myelin proteins in cervical lymph nodes of MS patients using ultrasound-guided fine-needle aspiration cytology. J. Neuroimmunol. 2005, 161(1-2):190-194.
13. Franchi L., et al. The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat. Immunol. 2009, 10(3):241-247.
14. Franchi L., Munoz-Planillo R., Nunez G. Sensing and reacting to microbes through the inflammasomes. Nat. Immunol. 2012, 13(4):325-332.
15. Furlan R., et al. Peripheral levels of caspase-1 mRNA correlate with disease activity in patients with multiple sclerosis; a preliminary study. J. Neurol. Neurosurg. Psychiatry 1999, 67(6):785-788.
16. Gris D., et al. NLRP3 plays a critical role in the development of experimental autoimmune encephalomyelitis by mediating Th1 and Th17 responses. J. Immunol. 2010, 185(2):974-981.
17. Guarda G., et al. Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity 2011, 34(2):213-223.
18. Howe C.L., Mayoral S., Rodriguez M. Activated microglia stimulate transcriptional changes in primary oligodendrocytes via IL-1beta. Neurobiol. Dis. 2006, 23(3):731-739.
19. Huang W.X., Huang P., Hillert J. Increased expression of caspase-1 and interleukin-18 in peripheral blood mononuclear cells in patients with multiple sclerosis. Mult. Scler. 2004, 10(5):482-487.
20. Inoue M., Shinohara M.L. NLRP3 Inflammasome and MS/EAE. Autoimmune Dis. 2013, 2013:p859145.
21. Inoue M., et al. NLRP3 inflammasome induces chemotactic immune cell migration to the CNS in experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. U. S. A. 2012, 109(26):10480-10485.
22. Liu J.S., et al. IFNs are critical regulators of IL-1 receptor antagonist and IL-1 expression in human microglia. J. Immunol. 1998, 161(4):1989-1996.
23. Mason J.L., et al. Interleukin-1beta promotes repair of the CNS. J. Neurosci. 2001, 21(18):7046-7052.
24. McGeachy M.J., et al. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat. Immunol. 2007, 8(12):1390-1397.
25. Molnarfi N., et al. Opposite effects of IFN beta on cytokine homeostasis in LPS- and T cell contact-activated human monocytes. J. Neuroimmunol. 2004, 146(1-2):76-83.
26. Nicoletti F., et al. Circulating serum levels of IL-1ra in patients with relapsing remitting multiple sclerosis are normal during remission phases but significantly increased either during exacerbations or in response to IFN-beta treatment. Cytokine 1996, 8(5):395-400.
27. Peelen E., et al. Effects of vitamin D on the peripheral adaptive immune system: a review. Autoimmun Rev. 2011, 10(12):733-743.
28. Polman C.H., et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol. 2011, 69(2):292-302.
29. Schroder K., Tschopp J. The inflammasomes. Cell 2010, 140(6):821-832.
30. Sciacca F.L., Canal N., Grimaldi L.M. Induction of IL-1 receptor antagonist by interferon beta: implication for the treatment of multiple sclerosis. J. Neurovirol. 2000, 6(Suppl. 2):S33-S37.
31. Smolders J., et al. Safety and T cell modulating effects of high dose vitamin D3 supplementation in multiple sclerosis. PLoS ONE 2010, 5(12):pe15235.
32. Smolders J., et al. Vitamin D-related gene expression profiles in immune cells of patients with relapsing remitting multiple sclerosis. J. Neuroimmunol. 2011, 235(1-2):91-97.
33. Smolders J., et al. Expression of vitamin D receptor and metabolizing enzymes in multiple sclerosis-affected brain tissue. J. Neuropathol. Exp. Neurol. 2013, 72(2):91-105.
34. Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat. Med. 2007, 13(2):139-145.
35. Strowig T., et al. Inflammasomes in health and disease. Nature 2012, 481(7381):278-286.
36. Takahashi J.L., et al. Interleukin-1beta promotes oligodendrocyte death through glutamate excitotoxicity. Ann. Neurol. 2003, 53(5):588-595.
37. Thewissen M., et al. Analyses of immunosenescent markers in patients with autoimmune disease. Clin. Immunol. 2007, 123(2):209-218.
38. Tzartos J.S., et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am. J. Pathol. 2008, 172(1):146-155.
39. Voltz R., et al. Multiple sclerosis: longitudinal measurement of interleukin-1 receptor antagonist. J. Neurol. Neurosurg. Psychiatry 1997, 62(2):200-201.